Last edition
News about "Dr. Mark Bunnage"
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
Dr. Mark Bunnage | 03/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members